Characteristics of kidney transplant outpatients from nephrology department, Hue Central hospital: A single-center study
Nội dung chính của bài viết
Tóm tắt
Kidney transplantation (KTx) is the optimal treatment for improving survival and quality of life for end-stage renal disease (ESRD) patients. A total of 289 kidney transplant recipients were followed in Nephrology Department, Hue Central Hospital, with a significant male predominance (73.36%). The mean age of the cohort was 41.6±11.27 years old, with most patients being between 20 and 40 years old. Among our study cohort, many patients maintained long-term graft function, with 199 patients (n= 68.86%) having a graft survival period of 2-5 years, and 73 patients maintaining graft function for more than 5 years. The average estimated glomerular filtration rate (eGFR) was 54.74±15.56 ml/min/1.73m2, with a corresponding serum creatinine level of 113.9±79.22 μmol/L. Metabolic complications were prevalent in the post-transplant period. Hyperglycemia was observed in 35.89% (n=103) of patients, dyslipidemia in 32.4% (n=93), and hyperuricemia in 46.34% (n=133). Post-transplant anemia (PTA) affected 24.74% (n=71) of patients with similar proportions across genders. Notably, post-transplant erythrocytosis (PTE) was found in 12.2% (n=35) of the cohort, with all affected patients being male. Our observational retrospective study indicates that metabolic-related and hematological complications are common in kidney transplant recipients. Improved management of these complications should be a key focus in post-transplant follow-up care.
Chi tiết bài viết
Từ khóa
Chronic kidney disease (CKD), end-stage renal disease (ESRD), Kidney transplantation (KTx), post-transplant metabolic disorders, post-transplant hematological complications
Tài liệu tham khảo
2. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369(13): 1215-1226. doi:10.1056/NEJMoa1302506.
3. Simforoosh N, Shemshaki H, Nadjafi-Semnani M, Sotoudeh M. Living related and living unrelated kidney transplantations: A systematic review and meta-analysis. World J Transplant. 2017; 7(2): 152-160. doi:10.5500/wjt.v7.i2.152.
4. Nguyen VL, Quang NN, Hai DV, Minh TT, Quang TL. Cadaveric kidney transplantation from 2010-2020 at Viet Duc University Hospital: our experience from Vietnam, a developing country. Korean J Transplant. 2022; 36(1): S20-S20. doi:10.4285/ATW2022.F-1057.
5. Cheung CY, Tang SCW. Personalized immunosuppression after kidney transplantation. Nephrology. 2022; 27(6): 475-483. doi:10.1111/nep.14035.
6. Malyszko J, Basak G, Batko K, et al. Haematological disorders following kidney transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2022; 37(3): 409-420. doi:10.1093/ndt/gfaa219.
7. Kanbay M, Siriopol D, Guldan M, et al. Prognostic impact of post-transplant diabetes mellitus in kidney allograft recipients: a meta-analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025; 40(3): 554-576. doi:10.1093/ndt/gfae185.
8. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366(9491): 1059-1062. doi:10.1016/S0140-6736(05)67402-8.
9. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4): 457-465. doi:10.1517/14740338.2016.1140743.
10. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol CJASN. 2009; 4(2): 481-508. doi:10.2215/CJN.04800908.
11. Hussain A, Culliford A, Phagura N, Evison F, Gallier S, Sharif A. Comparing survival outcomes for kidney transplant recipients with pre-existing diabetes versus those who develop post-transplantation diabetes. Diabet Med J Br Diabet Assoc. 2022; 39(2): e14707. doi:10.1111/dme.14707.
12. Lin H, Yan J, Yuan L, et al. Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data. Diabetol Metab Syndr. 2021; 13(1): 126. doi:10.1186/s13098-021-00742-4.
13. Chowdhury TA, Wahba M, Mallik R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Diabet Med J Br Diabet Assoc. 2021; 38(6): e14523. doi:10.1111/dme.14523.
14. Warden BA, Duell PB. Management of dyslipidemia in adult solid organ transplant recipients. J Clin Lipidol. 2019; 13(2): 231-245. doi:10.1016/j.jacl.2019.01.011.
15. Iannuzzo G, Cuomo G, Di Lorenzo A, et al. Dyslipidemia in Transplant Patients: Which Therapy? J Clin Med. 2022; 11(14): 4080. doi:10.3390/jcm11144080.
16. Mickiewicz A, Żegleń S, Kędzierska-Kapuza K, et al. Lipid-lowering agents in solid organ transplant recipients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025; 40(9): 1659-1671. doi:10.1093/ndt/gfaf104.
17. Malyszko J, Glowinska I, Mysliwiec M. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression? Transplant Proc. 2012; 44(10): 3013-3016. doi:10.1016/j.transproceed.2012.06.070.